Diabetic retinopathy

Diabetes Care

Volumn 27, Issue 10, 2004, Pages 2540-2553

  Fong, Donald S ^a   Aiello, Lloyd P ^b,c   Ferris III, Frederick L ^d   Klein, Ronald ^e  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

^b JOSLIN DIABETES CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d NATIONAL EYE INSTITUTE   (United States)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; ALPHA TOCOPHEROL; AMINOGUANIDINE; CHLORPROPAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIBENCLAMIDE; GLIPIZIDE; GLUCOSE; GROWTH HORMONE; INSULIN; LIPID; MIDOSTAURIN; PEGAPTANIB; PIGMENT EPITHELIUM DERIVED FACTOR; POLYOL; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; RANIBIZUMAB; REACTIVE OXYGEN METABOLITE; RUBOXISTAURIN; SOMATOMEDIN; SORBITOL; TRANSFORMING GROWTH FACTOR BETA; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIABETIC RETINOPATHY; ENZYME ACTIVATION; ENZYME ACTIVITY; EYE PHOTOGRAPHY; FILM; FLUORESCENCE ANGIOGRAPHY; GLYCEMIC INDEX; HUMAN; HYPERTENSION; KIDNEY DISEASE; LIPID BLOOD LEVEL; NERVE INJURY; NONHUMAN; OPHTHALMOSCOPY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RETINOPATHY; REVIEW; STEREOMICROSCOPY; TOMOGRAPHY; VASCULAR DISEASE; VITRECTOMY; VITREOUS HEMORRHAGE;

COMBINED MODALITY THERAPY; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE PROGRESSION; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; LASER COAGULATION; MALE; MONITORING, PHYSIOLOGIC; OPHTHALMOSCOPY; PRACTICE GUIDELINES; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; VISUAL ACUITY; VITRECTOMY; VITREORETINOPATHY, PROLIFERATIVE;

EID: 4644316459     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.10.2540     Document Type: Review

References (135)

1. American Diabetes Association: All about diabetes [webpage]. Available from http://www.diabetes.org/about-diabetes. jsp. Accessed 16 January 2004
2. Harris MI: Undiagnosed NIDDM: clinical and public health issues. Diabetes Care 16:642-652, 1993
3. Frank RN, Keirn RJ, Kennedy RA, Frank KW: Galactose induced retinal basement membrane thickening: prevention by sorbinil. Invest Ophthalmol Vis Sci 24: 1519-1524, 1983
4. Engerman RL, Kern TS: Experimental galactosemia produces diabetic-like retinopathy. Diabetes 33:97-100, 1984
5. Gabbay KH: Hyperglycemia, polyol metabolism, and complications of diabetes mellitus. Annu Rev Med 26:521-536, 1975
6. Tomlinson DR, Willars GB, Carrington AL: Aldose reductase inhibitors and diabetic complications. Pharmacol Ther 54: 151-194, 1992
7. Arauz-Pacheco C, Ramirez LC, Pruneda L, Sanborn GE, Rosenstock J, Raskin P: The effect of the aldose reductase inhibitor, ponalrestat, on the progression of diabetic retinopathy. J Diabetes Complications 6:131-137, 1992
8. A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy: the Sorbinil Retinopathy Trial Research Group. Arch Ophthalmol 108: 1234-1244, 1990
9. Brownlee M, Vlassara H, Cerami A: Non-enzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med 101:527-537, 1984
10. Wautier JL, Guillausseau PJ: Advanced glycation end products, their receptors and diabetic angiopathy. Diabete Metab 27:535-542, 2001
11. Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M: Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci U S A 88:11555-11558, 1991
12. Freedman BI, Wuerth JP, Cartwright K, Bain RP, Dippe S, Hershon K, Mooradian AD, Spinowitz BS: Design and baseline characteristics for the Amino-guanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials 20:493-510, 1999
13. Raskin P, Caltran D, William M, et al.: Pimagedine reduces progression of retinopathy and lowers lipid concentrations in patients with type I diabetes (Abstract). J Am Soc Nephrol 10:179A, 1999
14. Giugliano D, Ceriello A, Paolisso G: Oxidative stress and diabetic vascular complications. Diabetes Care 19:257-267, 1996
15. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404:787-790, 2000
16. Kunisaki M, Bursell SE, Clermont AC, lshii H, Ballas LM, Jirousek MR, Umeda F, Nawata H, King GL: Vitamin E prevents diabetes-induced abnormal retinal blood flow via the diacylglycerol-protein kinase C pathway. Am J Physiol 269: E239-E246, 1995
17. Bursell SE, King GL: Can protein kinase C inhibition and vitamin E prevent the development of diabetic vascular complications? Diabetes Res Clin Pract 45:169-182, 1999
18. Bursell SE, Clermont AC, Aiello LP, Aiello LM, Schlossman DK, Feener EP, Laffel L, King GL: High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes. Diabetes Care 22:1245-1251, 1999
19. Lonn E, Yusuf S, Hoogwerf B, Pogue J, Yi Q, Zinman B, Bosch J, Dagenais G, Mann JF, Gerstein HC, the HOPE investigators: Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care 25:1919-1927, 2002
20. Ways DK, Sheetz MJ: The role of protein kinase C in the development of the complications ofdiabetes. Vitam Horm 60: 149-193, 2000
21. Shiba T, Inoguchi T, Sportsman JR, Heath WF, Bursell S, King GL: Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am J Physiol 265:E783-E793, 1993
22. Inoguchi T, Battan R, Handler E, Sportsman JR, Heath W, King GL: Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci U S A 89:11059-11063, 1992
23. Xia P, Aiello LP, Ishii H, Jiang ZY, Park DJ, Robinson GS, Takagi H, Newsome WP, Jirousek MR, King GL: Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 98:2018-2026, 1996
24. Miller JW, Adamis AP, Aiello LP: Vascular endothelial growth factor in ocular neovascularization andproliferative diabetic retinopathy. Diabete Metab Rev 13: 37-50, 1997
25. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, et al: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480-1487, 1994
26. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, et al.: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480-1487, 1994
27. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, Smith LE: Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A 92: 10457-10461, 1995
28. Aiello LP, Bursell SE, Clermont A, Duh E, Ishii H, Takagi C, Mori F, Ciulla TA, Ways K, Jirousek M, Smith LE, King GL: Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform-selective inhbitor. Diabetes 46:1473-1480, 1997
29. Sharp PS, Fallon TJ, Brazier OJ, Sandler L, Joplin GF, Kohner EM: Long term follow-up of patients who underwent yttrium-90 pituitary implantation for treatment of proliferative diabetic retinopathy. Diabetologia 30:199-207, 1987
30. Chew EY, Mills JL, Metzger BE, Remaley NA, Jovanovic-Peterson L, Knopp RH, Conley M, Rand L, Simpson JL, Holmes LB Aarons JH, the National Institute of Child Health and Human Development Diabetes in Early Pregnancy Study Group: Metablolic control and progression of retinopathy: the Diabetes in Early Pregnancy Study. Diabetes Care 18:631-637, 1995
31. Chantelau E: Evidence that upregulation of serum IGF-1 concentration causes acceleration of diabetic retinopathy. Br J Ophthalmol 82:725-730, 1998
32. McCombe M, Lightman S, Eckland DJ, Hamilton AM, Lightman SL: Effect of a long-acting somatostatin analogue (BIM23014) on proliferative diabetic retinopathy: a pilot study. Eye 5:569-575, 1991
33. Mallet B, Vialettes B, Haroche S, Escoffier P, Gastaut P, Taubert JP, Vague P: Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201-995. Diabetes Metab 18:438-444, 1992
34. Growth Hormone Antagonist for Proliferative Diabetic Retinopathy Study Group: The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy. Ophthalmology 108: 2266-2272, 2001
35. Grant MB, Mames RN, Fitzgerald C, Hazariwala KM, Cooper-DeHoff R, Caballero S, Estes KS: The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care 23: 504-509, 2000
36. Spranger J, Meyer-Schwickerath R, Klein M, Schatz H, Pfeiffer A: Deficient activation and different expression of transforming growth factor-B isoforms in active proliferative diabetic retinopathy and neovascular eye disease. Exp Clin Endocrinol 107:21-28, 1999
37. Sharp PS: Growth factors in the pathogenesis of diabetic retinopathy. Diabetes Review 3:164-176, 1995
38. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP: Pigment epithelium-derived growth factor: a potent inhibitor of angiogenesis. Science 285:245-248, 1999
39. Stellmach V, Crawford SE, Zhou W, Bouck N: Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc Natl Acad Sci U S A 98:2593-2597, 2001
40. Aiello LP, Gardner TW, King GL, Blankenship G, Cavallerano JD, Ferris FL 3rd, Klein R: Diabetic retinopathy. Diabetes Care 21:143-156, 1998
41. 4L Early Treatment Diabetic Retinopathy Study Research Group: Grading diabetic retinopathy from stereoscopic color fundus photographs - an extension of the modified Airlie House classification: ET-DRS report number 10. Ophthalmology 98:786-806, 1991
42. Hutchinson A, McIntosh A, Peters J, O'Keeffe C, Khunti K, Baker R, Booth A: Effectiveness of screening and monitoring tests for diabetic retinopathy: a systematic review. Diabet Med 17:495-506, 2000
43. Sussman EJ, Tsiaras WG, Soper KA: Diagnosis of diabetic eye disease. JAMA 247:3231-3234, 1982
44. Bursell SE, Cavallerano JD, Cavallerano AA, Clermont AC, Birkmire-Peters D, Aiello LP, Aiello LM, the Joslin Vision Network Research Team: Stereo non-mydriatic digital-video color retinal imaging compared with Early Treatment Diabetic Retinopathy Study seven standard field 35-mm stereo color photos for determining level of diabetic retinopathy. Ophthalmology 108:572-585, 2001
45. Cavallerano AA, Cavallerano JD, Katalinic P, Tolson AM, Aiello LP, Aiello LM, the Joslin Vision Network Clinical Team: Use of Joslin Vision Network digital-video nonmydriatic retinal imaging to assess diabetic retinopathy in a clinical program. Retina 23:215-223, 2003
46. Fransen SR, Leonard-Martin TC, Feuer WJ, Hildebrand PL: Clinical evaluation of patients with diabetic retinopathy: accuracy of the Inoveon diabetic retinopathy-3DT system. Ophthalmology 109: 595-601, 2002
47. Zeimer R, Zou S, Meeder T, Quinn K, Vitale S: A fundus camera dedicated to the screening of diabetic retinopathy in the primary-care physician's office. Invest Ophthalmol Vis Sci 43:1581-1587, 2002
48. Lin DY, Blumenkranz MS, Brothers RJ, Grosvenor DM: The sensitivity and pecificity of single-field nonmydriatic monochromatic digital fundus photography with remote image interpretation for diabetic retinopathy screening: a comparison with ophthalmoscopy and standardized mydriatic color photography. Am J Ophthalmol 134:204-213, 2002
49. Taylor DJ, Fisher J, Jacob J, Tooke JE: The use of digital cameras in a mobile retinal screening environment. Diabet Med 16:680-686, 1999
50. Pugh JA, Jacobson JM, Van Heuven WA, Watters JA, Tuley MR, Lairson DR, Lorimor RJ, Kapadia AS, Velez R: Screening for diabetic retinopathy: the wide-angle retinal camera. Diabetes Care 16:889-895, 1993
51. 50a. Joannou J, Kalk WJ, Mahomed I, Ntsepo S, Berzin M, Joffe BI, Raal FJ, Sachs E, van der Merwe MT, Wing JR: Screening for diabetic retinopathy in South Africa with 60 degrees retinal colour photography. J Intern Med 239:43-47, 1996
52. Singer DE, Nathan DM, Fogel HA, Schachat AP: Screening for diabetic retinopathy. Ann Int Med 116:660-671, 1992
53. Javitt JC, Aiello LP: Cost effectiveness of detecting and treating diabetic retinopathy. Ann Intern Med 124:164-169, 1995
54. Javitt JC, Aiello LP, Chiang Y, Ferris FL 3rd, Canner JK, Greenfield S: Preventative eye care n people with diabetes is cost-saving to the federal government: implications for healthcare reform. Diabetes Care 17:909-917, 1994
55. Diabetic Retinopathy Study Group: Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study (DRS) findings: DRS Report 8. Ophthalmol 88: 583-600, 1981
56. ETDRS Research Group: Photocoagulation for diabetic macular edema. Arch Ophthalmol 193:1796-1806, 1985
57. Witkin SR, Klein R: Ophthalmologic care for persons with diabetes. JAMA 251:2534-2537, 1984
58. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. VI. Retinal photocoagulation. Ophthalmol 94:747-753, 1987
59. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL: The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 102:520-526, 1984
60. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL: The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 102:527-532, 1984
61. Batchelder T, Barricks M: The Wisconsin Epidemiologic Study of Diabetic Retinopathy (Letter). Arch Ophthalmol 113: 702-703, 1995
62. Vijan S, Hofer TP, Hayward RA: Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA 283: 889-896, 2000
63. Drammond M: Consultant Report to the National Eye Institute, 1987. Bethesda, MD, National Institutes of Health, 1987
64. The Diabetic Retinopathy Study Research Group: A modification of the Airlie House classification of diabetic retinopathy (DRS report no. 7). Invest Ophthalmol Vis Sci 21:210-226, 1981
65. Verdaguer TJ: Screening para retinopatia diabetica en Latino America: resultados: Revista da Sociedade Brasileira de Retina e Vitreo. 4:14-15, 2001
66. Fukuda M: Clinical arrangement of classification of diabetic retinopathy. Tohoku J Exp Med 141:331-335, 1983
67. National Health and Medical Research Council: Clinical Practice Guidelines: Management of Diabetic Retinopathy. Canberra, Australia, National Health and Medical Research Council, 1997
68. Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, Davis M, Dills D, Kampik A, Pararajasegaram R, Verdaguer JT, the Global Diabetic Retinopathy Project Group: Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110:1677-1682, 2003
69. Huang D, Swanson EA, Lin CP, Schuman JS, Stinson WG, Chang W, Hee MR, Flotte T, Gregory K, Puliafito CA, et al.: Optical coherence tomography. Science 254:1178-1181, 1991
70. Rivellese M, George A, Reichel E, Puliafito C: Optical coherence tomography after laser photocoagulation for clinically significant macular edema. Ophthalmic Surg Lasers 31:192-197, 2000
71. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL: Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA 260: 2864-2871, 1988
72. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986, 1993
73. The Diabetes Control and Complications Trial Research Group: Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology 102:647-661, 1995
74. The U.K. Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes: U.K. Prospective Diabetes Study report no.33. Lancet 352:837-853, 1998
75. The Diabetes Control and Complicatins Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
76. The Diabetes Control and Complications Trial/Epidemiology of Diabetes and Complications Research Group: Retinopathy and nephropathy in patients with type I diabetes four years after a trail of intensive therapy. N Engl J Med 342:381-389, 2000
77. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): U.K. Prospective Diabetes Study (UKPDS) Group. Lancet 352:837-853, 1998
78. The Diabetes Control and Complication Trial Research Group: The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 45:1289-1298, 1996
79. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412, 2000
80. American Diabetes Association: Standards of medical care in diabetes. Diabetes Care 27 (Suppl. 1):S15-S35, 2004
81. Klein R, Klein BE, Moss SE, Cruickshanks KJ: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 105:1801-1815, 1998
82. Klein R, Klein BE, Moss SE, Cruickshanks KJ: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema Ophthalmology 102:7-16, 1995
83. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38: UK Prospective Diabetes Study Group. BMJ 317:703-713, 1998
84. The United Kingdom Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: United Kingdom Prospective Diabetes Study report no. 38. BMJ 317: 703-713, 1998
85. Aiello LP, Cahill MT, Wong JS: Systemic considerations in the management of diabetic retinopathy. Am J Ophthalmol 132: 760-776, 2001
86. The United Kingdom Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: United Kingdom Prospective Diabetes Study report no. 39. BMJ 317:713-720, 1998
87. Estacio RO, Jeffers BW, Gifford N, Schrier RW: Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 23: B54-B64, 2000
88. Schrier RW, Estacio RO, Esler A, Mehler P: Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 61:1086-1097, 2002
89. Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, Rogulja-Pepeonik Z, Fuller JH: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes: the EUCLID Study Group: EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 351:28-31, 1998
90. Klein R, Klein BEK: Blood pressure control and diabetic retinopathy. Br J Ophthalmol 86:365-367, 2002
91. Action to Control Cardiovascular Risk in Diabetes (ACCORD) [website]. Available from www.accordtrial.org. Accessed May 2004
92. Sjolie AK, Chaturvedi N, Fuller J: Effect of lisinopril on progression of retinopathy and microalbuminuria in normotensive subjects with insulin-dependent diabetes mellitus. Ugeskr Laeger 161: 949-952, 1999
93. The Microalbuminuria Collaborative Study Group: Predictors of the development of microalbuminuria in patients with type I diabetes mellitus: a seven-year prospective study. Diabet Med 16: 918-925, 1999
94. Klein R, Klein BEK, Moss SE, Cruickshanks KJ: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. V. Proteinuria and retinopathy in a population of diabetic persons diagnosed prior to 30 years of age. In Diabetic Renal-Retinal Syndrome 3. Freidman EA, L'Esperance FA, Eds. Orlando, FL, Grune & Stratton, 1986
95. Mathiesen ER, Ronn B, Storm B, Foght H, Deckert T: The natural course of microalbuminuria in insulin-dependent diabetes: a 10 year prospective study. Diabet Med 12:482-487, 1995
96. Klein R, Klein BEK, Moss SE, Cruickshanks KJ: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XVII. the 14 year incidence and progression of diabetic retinopathy and associated risk factors in type I diabetes. Ophthalmology 105:1801-1815, 1998
97. Pradhan R, Fong D, March C, Jack R, Rezapour G, Morris K, Davidson MB: Angiotensin-converting enzyme inhibition for the treatment of moderate to severe diabetic retinopathy in normotensive type 2 diabetic patients: a pilot study. J Diabetes Complications 16:377-381, 2002
98. Hogeboom van Buggenum IM, Polak BC, Reichert-Thoen JW, de Vries-Knoppert WA, van Hinsbergh VW, Tangelder GJ: Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy. Diabetologia 45:203-209, 2002
99. Chaturvedi N, Fuller JH, Pokras F, Rottiers R, Papazoglou N, Aiello LP, the EUCLID Study Group: Circulating plasma vascular endothelial growth factor and microvascular complications of type 1 diabetes mellitus: the influence of ACE inhibition. Diabet Med 18:288-294, 2001
100. Chase HP, Garg SK, Harris S, Hoops S, Jackson WE, Holmes DL: Angiotensin-converting enzyme inhibitor treatment for young normotensive diabetic subjects: a two-year trial. Ann Ophthalmol 25:284-289, 1993
101. Larsen M, Hommel E, Parving HH, Lund-Anderson H: Protective effect of captopril on the blood-retina barrier in normotensive insulin-dependent diabetic patients with nephropathy and background retinopathy. Graefes Arch Clin Exp Ophthalmol 228:505-509, 1990
102. Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R: Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 158:998-1004, 1998
103. Chowdhury TA, Hopkins D, Dodson PM, Vafidis GC: The role of serum lipids in exudative diabetic maculopathy: is there a place for lipid lowering therapy? Eye 16:689-693, 2002
104. Harold M, Marmion VJ, Gough KR: A double-blind controlled trial of clofibrate in the treatment of diabetic retinopathy. Diabetes 84:285-291, 1969
105. Cullen JF, Ireland JT, Oliver MF: A controlled trial of atromid therapy in exudative diabetic retinopathy. Trans Ophthalmol Soc UK 84:281-295, 1964
106. Duncan LJ, Cullen JF, Ireland JT: A three-year trial of atromid therapy in exudative diabetic retinopathy. Diabetes 17:458-467, 1968
107. Klein BE, Moss SE, Klein R, Surawicz TS: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudates. Ophthalmology 98:1261-1265, 1991
108. Chew EY, Klein ML, Ferris FL 3rd, Remaley NA, Murphy RP, Chantry K, Hoogwerf BJ, Miller D: Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy: the Early Treatment Diabetic Retinopathy Study (ETDRS) report no. 22. Arch Ophthalmol 114:1079-1084, 1996
109. Fong DS, Segal PP, Myers F, Ferris FL, Hubbard LD, Davis MD: Subretinal fibrosis in diabetic macular edema: ET-DRS report no. 23: the Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol 115:873-877, 1997
110. Jirousek MR, Gillig JR, Gonzalez CM, Heath WF, McDonald JH 3rd, Neel DA, Rito CJ, Singh U, Stramm LE, Melikian-Badalian A, Baevsky M, Ballas LM, Hall SE, Winneroski LL, Faul MM: (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro- 4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13] oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. J Med Chem 39:2664-2671, 1996
111. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell SE, Kern TS, Ballas LM, Heath WF, Stramm LE, Feener EP, King GL: Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 272: 728-731, 1996
112. Aiello LP, Bursell SE, Clermont A, Duh E, Ishii H, Takagi C, Mori F, Ciulla TA, Ways K, Jirousek M, Smith LE, King GL: Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform-selective inhibitor. Diabetes 46:1473-1480, 1997
113. Danis RP, Bingaman DP, Jirousek M, Yang Y: Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531. Invest Ophthalmol Vis Sci 39: 171-179, 1998
114. Aiello LP, Bursell S, Devries T, Alatorre C, King GL, Ways K: Protein kinase C beta selective inhibitor LY333531 ameliorates abnormal retinal hemodynamics in patients with diabetes (Abstract). Diabetes 48:A19, 1999
115. Fabbro D, Ruetz S, Bodis S, Pruschy M, Csermak K, Man A, Campochiaro P, Wood J, O'Reilly T, Meyer T: PKC412: a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 15:17-28, 2000
116. Seo MS, Kwak N, Ozaki H, Yamada H, Okamoto N, Yamada E, Fabbro D, Hofmann F, Wood JM, Campochiaro PA: Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. Am J Pathol 154:1743-1753, 1999
117. Propper DJ, McDonald AC, Man A, Thavasu P, Balkwill F, Braybrooke JP, Caponigro F, Graf P, Dutreix C, Blackie R, Kaye SB, Ganesan TS, Talbot DC, Harris AL, Twelves C: Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol 19: 1485-1492, 2001
118. The Eyetech Study Group: Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 22: 143-152, 2002
119. Nauck M, Karakiulakis G, Perruchoud A, Papakonstantinou E, Roth M: Corticosteriods inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Euro J Pharmacol 341:309-315, 1998
120. Nauck M, Roth M, Tamm M, Eickelberg O, Wieland H, Stulz P, Perruchoud AP: Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids. Am J Resp Cell Mol Biol 16:398-406, 1997
121. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, Baumal C: Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 109:920-927, 2002
122. Jonas J, Kreissig I, Sofker A, Degenring R: Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 121:57-61, 2003
123. Massin P, Audren F, Haouchine B, Erginay A, Bergmann JF, Benosman R, Caulin C, Gaudric A: Intravitreal triamcinolone acetonide for diabetic diffuse macular edema. Ophthalmology 111: 218-225, 2004
124. Diabetic Retinopathy Clinical Research Network [website]. Available from www.drcr.net.
125. Schepens CL, Avila MP, Trempe CC: Role of the vitreous in cystoid macular edema. Surv Ophthalmol 28:499-504, 1984
126. Nasrallah FP, Jalkh AE, Van Coppenolle F, Kado M, Trempe CL, McMeel JW, Schepens CL: The role of vitreous in diabetic macular edema. Ophthalmology 95:1335-1339, 1988
127. Hikichi T, Fujio N, Akiba J, Azuma Y, Takahashi M, Yoshida A: Association between the short-term natural history of diabetic macular edema and the vitreomacular relationship in type II diabetes mellitus. Ophthalmology 104:473-478, 1997
128. Kaiser PK, Riemann CD, Sears JE, Lewis H: Macular traction detachment and diabetic macular edema associated with posterior hyaloidal traction. Am J Ophthalmol 131-44-49, 2001
129. Lewis H, Abrams GW, Blumenkranz MS, Campo RV: Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology 99:753-759, 1992
130. Harbour JW, Smiddy WE, Flynn HW Jr, Rubsamen PE: Vitrectomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane. Am J Ophthalmol 121:405-443, 1996
131. Ikeda T, Sato K, Katano T, Hayashi Y: Vitrectomy for cystoid macular oedema with attached posterior hyaloid membrane in patients with diabetes. Br J Ophthalmol 83:12-14, 1999
132. Tachi N, Ogino N: Vitrectomy for diffuse macular edema in cases of diabetic retinopathy. Am J Ophthalmol 122:258-260, 1996
133. Tachi N: Surgical management of macular edema. Semin Ophthalmol 13:20-30, 1998
134. van Effenterre G, Guyot-Argenton C, Guiberteau B, Hany I, Lacotte JL: [Macular edema caused by contraction of the posterior hyaloid in diabetic retinopathy: surgical treatment of a series of 22 cases]. J Fr Ophthalmol 16:602-610, 1993 [article in French]
135. Pendergast SD, Hassan TS, Williams GA, Cos MS, Margherio RR, Ferrone PJ, Garretson BR, Trese MT: Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid. Am J Ophthalmol 130:178-186, 2000